| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00216762 Details | 2015-09-02 Interventional | 1/2 | [3 Refs] | - | Rituximab Chronic Urticar… Urticaria | Full Clinical Hold - | ||
| NCT00986778 Details | 2015-09-01 Interventional | 4 | 0 | Adefovir Entecavir Lamivudine Hepatitis Hepatitis B Hepatitis B, Ch… | Business Objectives Changed - | |||
| NCT01348503 Details | 2015-08-31 Interventional | 1 | 5 | Lenalidomide Sorafenib Carcinoma Carcinoma, Hepa… Hepatocellular … | Treatment was ineffective - | |||
| NCT00391313 2006-002624-42 Details | 2015-08-28 Interventional | 3 | - | Chloroquine Chikungunya Fev… Chikungunya Vir… | Terminated Chikungunya diseases has regressed and no more patients was suffering - | |||
| NCT01281163 Details | 2015-08-27 Interventional | 1 | 4 | Lapatinib Breast Neoplasm… Estrogen Recept… Estrogen Recept… HER2/Neu Positi… Progesterone Re… Progesterone Re… Recurrent Breas… Stage IV Breast… | - - | |||
| NCT00983047 Details | 2015-08-27 Interventional | 2 | 30 | Docetaxel Nimotuzumab Carcinoma, Non-… Lung Neoplasms Advanced Non-Sm… | The sponsor decide to terminate - | |||
| NCT00050336 Details | 2015-08-27 Interventional | 3 | 702 | Lonafarnib Carcinoma, Non-… Lung Neoplasms Neoplasm Metast… Carcinoma, Non-… Metastases, Neo… | - - | |||
| NCT01575028 Details | 2015-08-24 Interventional | 2 | 3 | Bupivacaine Ropivacaine Appendicitis | The study was allowed to expire due to changes in standard care for the patient population
within the NCH institution. - | |||
| NCT01172509 Details | 2015-08-21 Interventional | 1 | 6 | Baclofen Autism | too much variability in the TMS measures - | |||
| NCT00475917 Details | 2015-08-21 Interventional | 1 | 28 | Gemcitabine Neoplasms Cancer Lymphoma | - - | |||
| NCT02109224 Details | 2015-08-20 Interventional | 1 | 72 | Ibrutinib Acquired Immuno… Burkitt Lymphom… Castleman Disea… HIV Infections Hyperplasia Infections Intraocular Lym… Leukemia Leukemia, Hairy… Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, B-Cel… Lymphoma, B-Cel… Lymphoma, Folli… Lymphoma, Large… Lymphoma, Large… Lymphoma, Mantl… Lymphoma, Non-H… Lymphomatoid Gr… Multiple Myelom… Plasmablastic L… Precursor Cell … Recurrence Waldenstrom Mac… Adult B Acute L… Chronic Lymphoc… Cutaneous B-Cel… Extranodal Marg… HIV Infection Multicentric An… Nodal Marginal … Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Grade… Recurrent Grade… Recurrent Grade… Recurrent Mantl… Recurrent Margi… Recurrent Small… Refractory Chro… Refractory Hair… Refractory Plas… Small Intestina… Splenic Margina… Testicular Lymp… | Inadequate accrual rate - | |||
| NCT00542711 Details | 2015-08-20 Interventional | 1 | 0 | Curcumin Healthy | Technical difficulties - | |||
| NCT00954005 Details | 2015-08-19 Interventional | 1/2 | 56 | Gemcitabine Oxaliplatin Rituximab Lymphoma Indolent Lympho… | Predefined termination criterion of > 10 patients without CR or PR was matched. - | |||
| NCT01754623 Details | 2015-08-13 Interventional | 2 | 9 | Capecitabine Docetaxel Fluorouracil Gemcitabine Pancreatic Neop… Pancreatic Canc… | Lack of pre-treatment tissue to make the study plan feasible. The study only accrued 9 (of planned 35) participants. It was not possible to collect adequate pre-treatment tissue for radiosensitivity index (RSI) analysis, pre-treatment. The study was terminated before planned completion. | |||
| NCT01666236 Details | 2015-08-13 Interventional | 4 | [1 Refs] | 0 | Ranibizumab Triamcinolone Verteporfin Choroidal Neova… Dissociative Di… Neovascularizat… Polypoidal Chor… Retinal Detachm… Vascular Diseas… Retinal Pigment… | Lack of resources - | ||
| NCT01117987 2009-018167-26 Details | 2015-08-13 Interventional | 3 | 144 | Imatinib Mesyla… Familial Primar… Hypertension Pulmonary Arter… | Novartis discontinued the development of imatinib in PAH due to requirement of regulatory
authorities for additional data to secure marketing approval in PAH. Within primary outcome measure (OM) #1, an additional death (>30 days post study completion) was included in the imatinib arm. The participant flow and secondary OM #2 reflect deaths that occurred up to and including 30 days post study completion. | |||
| NCT01392495 2010-021960-14 Details | 2015-08-10 Interventional | 3 | 17 | Imatinib Mesyla… Familial Primar… Hypertension Pulmonary Arter… | Novartis discontinued the development of imatinib in PAH due to requirement of regulatory
authorities for additional data to secure marketing approval in PAH. - | |||
| NCT01009203 Details | 2015-08-10 Interventional | 2 | [1 Refs] | 13 | Erlotinib Hydro… MTOR Inhibitors Sirolimus Temsirolimus Carcinoma Carcinoma, Squa… Squamous Cell C… | High patient withdrawal rate - | ||
| NCT00440440 Details | 2015-08-10 Interventional | 4 | 0 | Testosterone Hypogonadism Diabetes | study merged with another study - | |||
| NCT02062996 Details | 2015-08-07 Interventional | 2 | 0 | Oxymetazoline Phenylephrine Dental Anesthes… Intranasal Drug… Nasal Surgical … | Could not receive FDA approval for IND - |